Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma

LEUKEMIA & LYMPHOMA

TAYLOR & FRANCIS LTD

1. Leukemia and Lymphoma Society [6551-18]
2. American Cancer Society [127508-RSG-15-045-01-LIB]
3. UWCCC Trillium Fund for Myeloma Research
4. NIH [P30CA014520]